Prosecution Insights
Last updated: April 19, 2026

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
1
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18566898 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TFR1 BERTOGLIO, VALARIE E 1632 Non-Final OA Dec 04, 2023
18277394 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3 GENES SHIBUYA, MARK LANCE 1631 Non-Final OA Aug 16, 2023
18273631 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN SMITH, ADAM MICHAEL 1638 Non-Final OA Jul 21, 2023
18025990 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R MONTANARI, DAVID A 1632 Non-Final OA Mar 13, 2023
18025302 GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 MONTANARI, DAVID A 1632 Non-Final OA Mar 08, 2023
18010964 GENETICALLY MODIFIED NON-HUMAN ANIMAL EXPRESSING A B2M/FCRN FUSION PROTEIN GU, QINHUA 1633 Non-Final OA Dec 16, 2022
17790059 GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa/CD47 TINSLEY, BRENDAN THOMAS 1634 Final Rejection Jun 29, 2022

Managing BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month